Advertisement

Modern Immunohistochemistry in Targeted Therapy

  • Allen M. Gown
Reference work entry

Abstract

Immunohistochemistry is the application of antibodies with predefined specificities to tissue sections, coupled with the use of highly sensitive detection systems permitting visualization of the antibody target. While traditionally immunohistochemistry has been employed to identify cell type-specific proteins which can reveal the direction of differentiation of tumors, more recently immunohistochemistry has been employed as “companion diagnostics” to identify the presence or absence, or to quantify the amount, of targets of various targeted therapies for cancer. These include the estrogen (and progesterone) receptors in breast cancer, the target of agents such as tamoxifen; the HER2 transmembrane receptor expressed by a subset of breast (and other) cancers, the target of the humanized monoclonal antibody, trastuzumab; the mutated c-kit transmembrane receptor of gastrointestinal stromal tumors, the target of imatinib; and CD20, the molecule expressed by B cells and B cell malignancies, the target of the humanized monoclonal antibody, rituximab. The use and limitations of immunohistochemistry to predict response to these novel reagents is reviewed.

Keywords

Progesterone Receptor Core Needle Biopsy HER2 Overexpression Cold Ischemia Time Epitope Retrieval 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Further Reading

  1. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11:155–68.PubMedGoogle Scholar
  2. Allred D, Carlson R, Berry D, Burstein H, Edge S, Goldstein L, et al. NCCN task force report: estrogen receptor and progesterone receptor testing in breast cancer by immunohistochemistry. J Natl Compr Canc Netw. 2009;7(Suppl 6):S1–21.PubMedGoogle Scholar
  3. Apple S, Pucci R, Lowe A, Shintaku I, Shapourifar-Tehrani S, Moatamed N. The effect of delay in fixation, different fixatives, and duration of fixation in estrogen and progesterone receptor results in breast carcinoma. Am J Clin Pathol. 2011;135:592–8.PubMedCrossRefGoogle Scholar
  4. Badve S, Baehner F, Gray R, Childs B, Maddala T, Liu M, et al. Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol. 2008;26:2473–81.PubMedCrossRefGoogle Scholar
  5. Bartlett JMS, Brookes CL, Robson T, van de Velde CJH, Billingham LJ, Campbell FM, et al. Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane adjuvant multinational trial. J Clin Oncol. 2011;29:1531–8.PubMedCrossRefGoogle Scholar
  6. Bilous M, Ades C, Armes J, Bishop J, Brown R, Cooke B, et al. Predicting the HER2 status of breast cancer from basic histopathology data: an analysis of 1500 breast cancers as part of the HER2000 International Study. Breast. 2003;12:92–8.PubMedCrossRefGoogle Scholar
  7. Bloom K, Harrington D. Enhanced accuracy and reliability of HER-2/neu immunohistochemical scoring using digital microscopy. Am J Clin Pathol. 2004;121:620–30.PubMedCrossRefGoogle Scholar
  8. Brock JE, Hornick JL, Richardson AL, Dillon DA, Lester SC. A comparison of estrogen receptor SP1 and 1D5 monoclonal antibodies in routine clinical use reveals similar staining results. Am J Clin Pathol. 2009;132:396–401.PubMedCrossRefGoogle Scholar
  9. Burry RW. Immunocytochemistry: a practical guide for biomedical research. New York: Springer; 2009.Google Scholar
  10. Carlson RW, Moench SJ, Hammond ME, Perez EA, Burstein HJ, Allred DC, et al. HER2 testing in breast cancer: NCCN task force report and recommendations. J Natl Compr Canc Netw. 2006;4(Suppl 3):S1–22.Google Scholar
  11. Cheang MCU, Treaba DO, Speers CH, Olivotto IA, Bajdik CD, Chia SK, et al. Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. J Clin Oncol. 2006;24:5637–44.PubMedCrossRefGoogle Scholar
  12. Chen LL, Trent JC, Wu EF, Fuller GN, Ramdas L, Zhang W, et al. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res. 2004;64:5913–9.PubMedCrossRefGoogle Scholar
  13. Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med. 2008;359:613–26.PubMedCrossRefGoogle Scholar
  14. Collins LC, Botero ML, Schnitt SJ. Bimodal frequency distribution of estrogen receptor immunohistochemical staining results in breast cancer: an analysis of 825 cases. Am J Clin Pathol. 2005;123:16–20.PubMedCrossRefGoogle Scholar
  15. Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer. 2011;11:865–75.PubMedGoogle Scholar
  16. Davis TA, Czerwinski DK, Levy R. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin Cancer Res. 1999;5:611–5.PubMedGoogle Scholar
  17. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472–80.PubMedCrossRefGoogle Scholar
  18. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561–6.PubMedCrossRefGoogle Scholar
  19. Fang C, Xu W, Li J-Y. A systematic review and meta-analysis of rituximab-based immunochemotherapy for subtypes of diffuse large B cell lymphoma. Ann Hematol. 2010;89:1107–13.PubMedCrossRefGoogle Scholar
  20. Fitzgibbons P, Murphy D, Hammond M, Allred D, Valenstein P. Recommendations for validating estrogen and progesterone receptor immunohistochemistry assays. Arch Pathol Lab Med. 2010;134:930–5.PubMedGoogle Scholar
  21. Forstpointner R, Unterhalt M, Dreyling M, Böck H-P, Repp R, Wandt H, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood. 2006;108:4003–8.PubMedCrossRefGoogle Scholar
  22. Gao G, Liang X, Jiang J, Zhou X, Huang R, Chu Z, et al. A systematic review and meta-analysis of immunochemotherapy with rituximab for B-cell non-Hodgkin's lymphoma. Acta Oncol. 2010;49:3–12.PubMedCrossRefGoogle Scholar
  23. Gavrielides MA, Gallas BD, Lenz P, Badano A, Hewitt SM. Observer variability in the interpretation of HER2/neu immunohistochemical expression with unaided and computer-aided digital microscopy. Arch Pathol Lab Med. 2011;135:233–42.PubMedGoogle Scholar
  24. Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol. 2007;44:3823–37.PubMedCrossRefGoogle Scholar
  25. Goldstein NS, Ferkowicz M, Odish E, Mani A, Hastah F. Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma. Am J Clin Pathol. 2003;120:86–92.PubMedCrossRefGoogle Scholar
  26. Gown A. Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol. 2008;21(Suppl 2):S8–15.PubMedCrossRefGoogle Scholar
  27. Gown A, Goldstein L. The knowns and the unknowns in HER2 testing in breast cancer. Am J Clin Pathol. 2011;136:5–6.PubMedCrossRefGoogle Scholar
  28. Gown AM, Goldstein LC, Barry TS, Kussick SJ, Kandalaft PL, Kim PM, et al. High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system. Mod Pathol. 2008;21:1271–7.PubMedCrossRefGoogle Scholar
  29. Grillo-López AJ, Hedrick E, Rashford M, Benyunes M. Rituximab: ongoing and future clinical development. Semin Oncol. 2002;29:105–12.PubMedCrossRefGoogle Scholar
  30. Haines 3rd GK, Wiley E, Susnik B, Apple S, Frkovic-Grazio S, Reyes C, et al. HER2 in well differentiated breast cancer: is testing necessary? Breast Cancer Res Treat. 2008;112:551–6.PubMedCrossRefGoogle Scholar
  31. Hammond MEH, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28:2784–95.PubMedCrossRefGoogle Scholar
  32. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17:1474–81.PubMedGoogle Scholar
  33. Heinrich MC, Blanke CD, Druker BJ, Corless CL. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol. 2002;20:1692–703.PubMedCrossRefGoogle Scholar
  34. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003a;21:4342–9.PubMedCrossRefGoogle Scholar
  35. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen C-J, Joseph N, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003b;299:708–10.PubMedCrossRefGoogle Scholar
  36. Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106:3725–32.PubMedCrossRefGoogle Scholar
  37. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577–80.PubMedCrossRefGoogle Scholar
  38. Hodi Z, Chakrabarti J, Lee AHS, Ronan JE, Elston CW, Cheung KL, et al. The reliability of assessment of oestrogen receptor expression on needle core biopsy specimens of invasive carcinomas of the breast. J Clin Pathol. 2007;60:299–302.PubMedCrossRefGoogle Scholar
  39. Hsu SM, Raine L, Fanger H. A comparative study of the peroxidase-antiperoxidase method and an avidin-biotin complex method for studying polypeptide hormones with radioimmunoassay antibodies. Am J Clin Pathol. 1981a;75:734–8.PubMedGoogle Scholar
  40. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1981b;29:577–80.PubMedCrossRefGoogle Scholar
  41. Ibarra JA, Rogers LW. Fixation time does not affect expression of HER2/neu: a pilot study. Am J Clin Pathol. 2010;134:594–6.PubMedCrossRefGoogle Scholar
  42. Ibarra J, Rogers L, Kyshtoobayeva A, Bloom K. Fixation time does not affect the expression of estrogen receptor. Am J Clin Pathol. 2010;133:747–55.PubMedCrossRefGoogle Scholar
  43. Jazirehi AR, Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene. 2005;24:2121–43.PubMedCrossRefGoogle Scholar
  44. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 2001;344:1052–6.PubMedCrossRefGoogle Scholar
  45. Khoury T, Sait S, Hwang H, Chandrasekhar R, Wilding G, Tan D, et al. Delay to formalin fixation effect on breast biomarkers. Mod Pathol. 2009;22:1457–67.PubMedCrossRefGoogle Scholar
  46. Khoury T, Kulkarni S, Morrison C, Bshara W, Zakharia Y, Edge S. HER2 testing: how to reach a high concordance rate between immunohistochemistry and fluorescence in situ hybridization. Appl Immunohistochem Mol Morphol. 2011;19:424–30.PubMedCrossRefGoogle Scholar
  47. Köhler A, Lauritzen B, Van Noorden CJ. Signal amplification in immunohistochemistry at the light microscopic level using biotinylated tyramide and nanogold-silver staining. J Histochem Cytochem. 2000;48:933–41.PubMedCrossRefGoogle Scholar
  48. Lee AHS, Key HP, Bell JA, Hodi Z, Ellis IO. Concordance of HER2 status assessed on needle core biopsy and surgical specimens of invasive carcinoma of the breast. Histopathology. 2012;60:880–4.PubMedCrossRefGoogle Scholar
  49. Lehr H-A, Mankoff DA, Corwin D, Santeusanio G, Gown AM. Application of photoshop-based image analysis to quantification of hormone receptor expression in breast cancer. J Histochem Cytochem. 1997;45:1559–65.PubMedCrossRefGoogle Scholar
  50. Mann GB, Fahey VD, Feleppa F, Buchanan MR. Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer. J Clin Oncol. 2005;23:5148–54.PubMedCrossRefGoogle Scholar
  51. Mayer G, Bendayan M. Biotinyl-tyramide: a novel approach for electron microscopic immunocytochemistry. J Histochem Cytochem. 1997;45:1449–54.PubMedCrossRefGoogle Scholar
  52. Miwa S, Nakajima T, Murai Y, Takano Y, Sugiyama T. Mutation assay of the novel gene DOG1 in gastrointestinal stromal tumors (GISTs). J Gastroenterol. 2008;43:531–7.PubMedCrossRefGoogle Scholar
  53. Moatamed NA, Nanjangud G, Pucci R, Lowe A, Shintaku IP, Shapourifar-Tehrani S, et al. Effect of ischemic time, fixation time, and fixative type on HER2/neu immunohistochemical and fluorescence in situ hybridization results in breast cancer. Am J Clin Pathol. 2011;136:754–61.PubMedCrossRefGoogle Scholar
  54. Mohsin SK, Weiss H, Havighurst T, Clark GM, Berardo M, le Roanh D, et al. Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod Pathol. 2004;17:1545–54.PubMedCrossRefGoogle Scholar
  55. Motta G, Cea M, Moran E, Carbone F, Augusti V, Patrone F, et al. Monoclonal antibodies for non-Hodgkin's lymphoma: state of the art and perspectives. Clin Dev Immunol. 2010;2010:428253.PubMedCrossRefGoogle Scholar
  56. Onrust SV, Lamb HM, Balfour JA. Rituximab. Drugs. 1999;58:79–88.PubMedCrossRefGoogle Scholar
  57. Osamura R, Gown A. Personalized medicine-molecular targeted cancer therapy. J Cell Mol Med. 2009;13:4285.PubMedCrossRefGoogle Scholar
  58. Pauletti G, Godolphin W, Press MF, Slamon DJ. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene. 1996;13:63–72.PubMedGoogle Scholar
  59. Perez EA, Suman VJ, Davidson NE, Martino S, Kaufman PA, Lingle WL, et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol. 2006;24:3032–8.PubMedCrossRefGoogle Scholar
  60. Pertschuk LP, Feldman JG, Kim YD, Braithwaite L, Schneider F, Braverman AS, et al. Estrogen receptor immunocytochemistry in paraffin embedded tissues with ER1D5 predicts breast cancer endocrine response more accurately than H222Sp gamma in frozen sections or cytosol-based ligand-binding assays. Cancer. 1996;77:2514–9.PubMedCrossRefGoogle Scholar
  61. Polak JM, Van Noorden S. Introduction to Immunocytochemistry. 3rd ed. Oxford: Bios; 2003.Google Scholar
  62. Press MF, Slamon DJ, Flom KJ, Park J, Zhou J-Y, Bernstein L. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol. 2002;20:3095–105.PubMedGoogle Scholar
  63. Press MF, Sauter G, Bernstein L, Villalobos IE, Mirlacher M, Zhou J-Y, et al. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res. 2005;11:6598–607.PubMedCrossRefGoogle Scholar
  64. Qiu J, Kulkarni S, Chandrasekhar R, Rees M, Hyde K, Wilding G, et al. Effect of delayed formalin fixation on estrogen and progesterone receptors in breast cancer: a study of three different clones. Am J Clin Pathol. 2010;134:813–9.PubMedCrossRefGoogle Scholar
  65. Reddy JC, Reimann JD, Anderson SM, Klein PM. Concordance between central and local laboratory HER2 testing from a community-based clinical study. Clin Breast Cancer. 2006;7:153–7.PubMedCrossRefGoogle Scholar
  66. Renshaw S. Immunohistochemistry. Oxfordshire: Scion; 2007.Google Scholar
  67. Rhodes A, Jasani B, Balaton AJ, Barnes DM, Miller KD. Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening. J Clin Pathol. 2000a;53:688–96.PubMedCrossRefGoogle Scholar
  68. Rhodes A, Jasani B, Balaton AJ, Miller KD. Immunohistochemical demonstration of oestrogen and progesterone receptors: correlation of standards achieved on in house tumours with that achieved on external quality assessment material in over 150 laboratories from 26 countries. J Clin Pathol. 2000b;53:292–301.PubMedCrossRefGoogle Scholar
  69. Rhodes A, Jasani B, Barnes D, Bobrow L, Miller K. Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol. 2000c;53:125–30.PubMedCrossRefGoogle Scholar
  70. Rhodes A, Borthwick D, Sykes R, Al-Sam S, Paradiso A. The use of cell line standards to reduce HER-2/neu assay variation in multiple European cancer centers and the potential of automated image analysis to provide for more accurate cut points for predicting clinical response to trastuzumab. Am J Clin Pathol. 2004;122:51–60.PubMedCrossRefGoogle Scholar
  71. Ross JS, Fletcher JA. The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy. Semin Cancer Biol. 1999;9:125–38.PubMedCrossRefGoogle Scholar
  72. Sabattini E, Bisgaard K, Ascani S, Poggi S, Piccioli M, Ceccarelli C, et al. The EnVision++ system: a new immunohistochemical method for diagnostics and research. Critical comparison with the APAAP, ChemMate, CSA, LABC, and SABC techniques. J Clin Pathol. 1998;51:506–11.PubMedCrossRefGoogle Scholar
  73. Schulz H, Bohlius JF, Trelle S, Skoetz N, Reiser M, Kober T, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2007;99:706–14.PubMedCrossRefGoogle Scholar
  74. Shi SR, Key ME, Kalra KL. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem. 1991;39:741–8.PubMedCrossRefGoogle Scholar
  75. Shi SR, Imam SA, Young L, Cote RJ, Taylor CR. Antigen retrieval immunohistochemistry under the influence of pH using monoclonal antibodies. J Histochem Cytochem. 1995;43:193–201.PubMedCrossRefGoogle Scholar
  76. Shi SR, Cote RJ, Yang C, Chen C, Xu HJ, Benedict WF, et al. Development of an optimal protocol for antigen retrieval: a “test battery” approach exemplified with reference to the staining of retinoblastoma protein (pRB) in formalin-fixed paraffin sections. J Pathol. 1996;179:347–52.PubMedCrossRefGoogle Scholar
  77. Shi SR, Cote RJ, Taylor CR. Antigen retrieval immunohistochemistry: past, present, and future. J Histochem Cytochem. 1997;45:327–43.PubMedCrossRefGoogle Scholar
  78. Shi SR, Shi Y, Taylor CR. Antigen retrieval immunohistochemistry: review and future prospects in research and diagnosis over two decades. J Histochem Cytochem. 2011;59:13–32.PubMedCrossRefGoogle Scholar
  79. Skaland I, Nordhus M, Gudlaugsson E, Klos J, Kjellevold KH, Janssen EAM, et al. Evaluation of 5 different labeled polymer immunohistochemical detection systems. Appl Immunohistochem Mol Morphol. 2010;18:90–6.PubMedCrossRefGoogle Scholar
  80. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177–82.PubMedCrossRefGoogle Scholar
  81. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707–12.PubMedCrossRefGoogle Scholar
  82. Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003;22:7359–68.PubMedCrossRefGoogle Scholar
  83. Tawfik OW, Kimler BF, Davis M, Donahue JK, Persons DL, Fan F, et al. Comparison of immunohistochemistry by automated cellular imaging system (ACIS) versus fluorescence in-situ hybridization in the evaluation of HER-2/neu expression in primary breast carcinoma. Histopathology. 2006;48:258–67.PubMedCrossRefGoogle Scholar
  84. Taylor CR. Paraffin section immunocytochemistry for estrogen receptor: the time has come. Cancer. 1996;77:2419–22.PubMedCrossRefGoogle Scholar
  85. Taylor CR, Cote RJ. Immunomicroscopy: a diagnostic tool for the surgical pathologist. 3rd ed. Philadelphia: Saunders Elsevier; 2006.Google Scholar
  86. Taylor CR, Shi SR, Chen C, Young L, Yang C, Cote RJ. Comparative study of antigen retrieval heating methods: microwave, microwave and pressure cooker, autoclave, and steamer. Biotech Histochem. 1996;71:263–70.PubMedCrossRefGoogle Scholar
  87. Tedesco KL, Thor AD, Johnson DH, Shyr Y, Blum KA, Goldstein LJ, et al. Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial. J Clin Oncol. 2004;22:1071–7.PubMedCrossRefGoogle Scholar
  88. Turbin D, Leung S, Cheang M, Kennecke H, Montgomery K, McKinney S, et al. Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: a tissue microarray study of 3,484 cases. Breast Cancer Res Treat. 2007;110:417–26.PubMedCrossRefGoogle Scholar
  89. Tuveson DA, Willis NA, Jacks T, Griffin JD, Singer S, Fletcher CD, et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene. 2001;20:5054–8.PubMedCrossRefGoogle Scholar
  90. Umemura S, Itoh J, Itoh H, Serizawa A, Saito Y, Suzuki Y, et al. Immunohistochemical evaluation of hormone receptors in breast cancer: which scoring system is suitable for highly sensitive procedures? Appl Immunohistochem Mol Morphol. 2004;12:8–13.PubMedCrossRefGoogle Scholar
  91. van Oers MHJ, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006;108:3295–301.PubMedCrossRefGoogle Scholar
  92. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:719–26.PubMedCrossRefGoogle Scholar
  93. von Wasielewski R, Mengel M, Gignac S, Wilkens L, Werner M, Georgii A. Tyramine amplification technique in routine immunohistochemistry. J Histochem Cytochem. 1997;45:1455–9.CrossRefGoogle Scholar
  94. Vosse BAH, Seelentag W, Bachmann A, Bosman FT, Yan P. Background staining of visualization systems in immunohistochemistry: comparison of the avidin-biotin complex system and the EnVision + system. Appl Immunohistochem Mol Morphol. 2007;15:103–7.PubMedCrossRefGoogle Scholar
  95. Werner M, Chott A, Fabiano A, Battifora H. Effect of formalin tissue fixation and processing on immunohistochemistry. Am J Surg Pathol. 2000;24:1016–9.PubMedCrossRefGoogle Scholar
  96. West RB, Corless CL, Chen X, Rubin BP, Subramanian S, Montgomery K, et al. The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol. 2004;165:107–13.PubMedCrossRefGoogle Scholar
  97. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118–45.PubMedCrossRefGoogle Scholar
  98. Yaziji H, Goldstein LC, Barry TS, Werling R, Hwang H, Ellis GK, et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA. 2004;291:1972–7.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Allen M. Gown
    • 1
    • 2
  1. 1.PhenoPath LaboratoriesSeattleUSA
  2. 2.Department of PathologyUniversity of British ColumbiaVancouverCanada

Personalised recommendations